reduced SI enzymatic activity may trigger IBS symptoms via colonic accumulation of undigested disaccharides from starch and sucrose, resulting in fermentation with gas production and osmotic diarrhoea. This information holds potential for patients' stratification, and the identification of IBS subgroups better suited to benefit from specific dietary restrictions. For instance, diets low in short chain carbohydrates like the FODMAPs (fermentable oligo-, di-, mono-saccharides and polyols that are poorly absorbed in the small intestine) have been shown to be effective in reducing GI symptoms in some patients with IBS, 5 6 though this has not been studied in relation to SI genotype and/or function. While sucrose and, in part, starch are not specifically restricted in a standard low FODMAP diet, such a therapeutic approach may be less effective in individuals whose reduced SI activity contributes to symptoms. Hence, a low FODMAP diet may be less effective in patients with IBS carrying SI hypomorphic variants.
To test this hypothesis, we sought to re-evaluate results obtained in a previous randomised controlled trial of the low FODMAP diet in patients with IBS with diarrhoea (IBS-D), 7 on stratification of participants for SI genotype data. From the original study, 46 patients were selected for these new analyses (table 1), based on available full clinical information and high-quality genotype data from Illumina Infinium HumanCoreExome arrays, as previously reported. 3 Endpoints of interest were IBS-D symptom relief (≥50%) and reduction of abdominal pain (30%), both studied and defined as in the original investigation. 7 Based on available genotype data, we restricted the analysis to SI hypomorphic (pathogenic) variants as previously described, 3 and three rare (Arg774Gly [rs147207752]; Tyr975His [rs146785675]; Glu1414Lys [rs145734588]) and one common (Val15Phe [rs9290264]) such variants were detected in the low FODMAP treated cohort (table 1) . Due to the small sample size, we stratified patients into carriers and non-carriers of hypomorphic variants (either rare or common), and compared these groups for their response to dietary treatment. As shown in figure 1 , while an overall 52.2% of patients experienced adequate IBS-D symptoms relief, SI PostScript Figure 1 Decreased symptom relief in patients with IBS and diarrhoea carrying sucrase-isomaltase (SI) hypomorphic variants. Adequate symptom relief in low fermentable oligo-, di-, mono-saccharides and polyols treated individuals, stratified according to SI genotype into carriers and non-carriers of hypomorphic variants. *P=0.031 (one-tailed logistic regression analysis, adjusting for age, sex, body mass index and ethnicity).
carriers benefited significantly less than SI non-carriers from the low FODMAP diet, with respective response rates 43.5% vs 60.9% (p=0.031; OR=4.66). A similar trend was also observed for abdominal pain reduction, thought this did not reach statistical significance (50% in the whole cohort, 47.8% in SI carriers and 52.2% in SI non-carriers, p=0.231). Genotype data were also available for 39 patients (from the original study) who followed the modified National Institute for Health and Care Excellence (mNICE) dietary guidelines which also reduced carbohydrate consumption. 7 While trends similar to the low FODMAP-treated group were observed in these patients (not shown), a combined FODMAP-mNICE analysis strengthened the evidence of association between SI genotype and response outcome: the increased sample size allowed further stratification of patients into individual genotype groups, and this revealed a correlation between SI hypomorphic copy number and response rates which were lowest in patients carrying two copies (16.7%) versus patients with one (42.1%) or no copies (56.1%) (p=0.0039; OR=3.33).
In conclusion, we report initial evidence that carrying SI hypomorphic variants is associated with a threefold to fourfold reduction in the likelihood of responding to dietary approaches that restrict the intake of carbohydrates, particularly FODMAPs. While study limitations include small sample size and lack of mucosal disaccharidase measurements in patients, this may bear implications for the development of patient treatment stratification strategies in IBS.
